Fractyl Health Stock Forum

$Fractyl Health (GUTS.US)$ Fractyl Health: Results Show Sustained Maintenance of Weight Loss, Blood Sugar Levels at Week 13 in Dio Mice Given Rjva-001 & Continuing High Fat Diet

$Fractyl Health (GUTS.US)$
Oral Presentation
Title: Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
Presentation Date & Time: Tuesday, November 5, 2024, 10:45 am - 11:00 am (CDT)
Location: Henry B. Gonzalez Convention Center, Room 007
Poster Presentation
Title: Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
Presentation Date & Time: Sunday, November 3, 2024,...

$Fractyl Health (GUTS.US)$ $Pixie Dust Technologies (PXDT.US)$ $Oklo Inc (OKLO.US)$ $Revance Therapeutics (RVNC.US)$ $PROCEPT BioRobotics (PRCT.US)$ $Atlas Lithium (ATLX.US)$ $EyePoint Pharmaceuticals (EYPT.US)$ $Porch Group (PRCH.US)$ $Top Wealth Group Holding (TWG.US)$ $Global Mofy AI (GMM.US)$ $Monte Rosa Therapeutics (GLUE.US)$ $Evoke Pharma (EVOK.US)$ $Greenlane (GNLN.US)$ $Autonomix Medical (AMIX.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

$Fractyl Health (GUTS.US)$ Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
2 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintena...

$S&W Seed (SANW.US)$ $Fractyl Health (GUTS.US)$ $Volcon (VLCN.US)$ $Eterna Therapeutics (ERNA.US)$ $Lazydays (GORV.US)$ $Adagio Medical (ADGM.US)$ $EXCELFIN ACQUISITION CORP (XFIN.US)$ $Treasure Global (TGL.US)$ $HWH International (HWH.US)$ $iCoreConnect (ICCT.US)$
📊⚡️📊

$Fractyl Health (GUTS.US)$ Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure
Globe Newswire 8-Aug-2024

$Fractyl Health (GUTS.US)$ Reuters· 3 mins ago
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People With Obesity Who Discontinue GLP-1 Based Drugs

$Fractyl Health (GUTS.US)$ Too many obesity drugs nowadays…

$Fractyl Health (GUTS.US)$ Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024.                                             VIA GLOBENEWSWIRE Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42%

$Fractyl Health (GUTS.US)$ Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.